New drug cocktails aim to tackle tough myeloma

NCT ID NCT02343042

Ongoing Disease control Sponsor: Karyopharm Therapeutics Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the drug selinexor in combination with various standard treatments for multiple myeloma, a type of blood cancer. It involves 300 participants with either relapsed/refractory or newly diagnosed disease. The goal is to find safe and effective doses and to see if these combinations improve response rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Selinexor (also known as XPOVIO) combined with various standard myeloma drugs

What this could lead to

If successful, this could provide more effective treatment options for multiple myeloma patients, potentially improving response rates and delaying disease progression.

What could go wrong

This is an early-phase trial (1b/2) with many different drug combinations, so results may vary. Side effects from the combinations could be significant, and not all arms may prove effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Show contact details

Locations

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234, United States
Cancer Care Manitoba

Winnipeg, Manitoba, R3E 0V9, Canada
Columbia University

New York, New York, 10032, United States
Cross Cancer Institute / University of Alberta

Edmonton, Alberta, T6G 1Z2, Canada
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke Institute of Cancer/ Duke University

Durham, North Carolina, 27710, United States
Fred Hutch Cancer Center

Seattle, Washington, 98109, United States
Hackensack University Medical Center - John Theurer Cancer Center

Hackensack, New Jersey, 07601, United States
Jonnsson Comprehensive Cancer Center / University of Los Angeles

Los Angeles, California, 0095, United States
Maisonneuve-Rosemont Hospital

Montreal, Quebec, H1T 2M4, Canada
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Hospital of Newfoundland

St. John's, Newfoundland and Labrador, A1B 3V6, Canada
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada
Queen Elizabeth II Health Sciences Center

Halifax, Nova Scotia, B3H 2Y9, Canada
Royal Victoria Hospital / McGill University

Montreal, Quebec, H3A 1A1, Canada
Sarah Cannon- Tennessee Oncology Nashville

Nashville, Tennessee, 37203, United States
Swedish Cancer Institute

Seattle, Washington, 98109, United States
Tom Baker Cancer Center/Alberta Health Services

Calgary, Alberta, T2N 4Z6, Canada
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
University of North Carolina - Chapel Hill Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599, United States
University of Wisconsin School of Medicine and Public Health

Madison, Wisconsin, 53792, United States
Vancouver General Hospital

Vancouver, British Columbia, V5Z 1M9, Canada
Weill Cornell Medicine

New York, New York, 10065, United States
Wilmot Cancer Center/ University of Rochester

Rochester, New York, United States